Role of Trop-2 as an Actionable Biomarker in Solid Tumors

TROPHY U-01 cohort 1 is a phase 2 open-label study of sacituzumab govitecan in patients with metastatic urothelial cancer and disease progression after both platinum-based regimens and checkpoint inhibitors.

Aditya Bardia, MD, MPH, discusses the results of the ASCENT trial in triple-negative breast cancer.

Trophoblast cell surface antigen 2 is a glycoprotein that spans the epithelial membrane surface and plays a role in cell self-renewal, proliferation, and transformation.